Charles River Laboratories announced significant divestiture plans, selling its CDMO and Cell Solutions businesses to GI Partners, and certain European Discovery Services assets to IQVIA Holdings. The divestitures will reduce 2026 revenue by over $200 million but are expected to improve adjusted operating margins by at least 100 basis points and add approximately 10 cents to adjusted EPS. The company raised its fiscal 2026 adjusted earnings guidance to $10.80-$11.30.

The global pharmacovigilance market is projected to grow from USD 8.91 billion in 2025 to USD 24.69 billion by 2035, at a CAGR of 10.34%. Growth is driven by stringent regulatory requirements, increased adverse drug reaction incidents, and pharmaceutical industry expansion into emerging markets. The U.S. market alone is expected to reach USD 9.48 billion by 2035. Phase IV post-market surveillance and contract outsourcing services dominate the market segments.

The global clinical trials support software solutions market is valued at USD 14.31 billion in 2026 and is expected to reach USD 34.15 billion by 2035, growing at a 10.15% CAGR. North America leads the market while Asia Pacific shows the fastest growth. CTMS solutions dominate by product type, cloud-based delivery leads, and CROs lead by end-user segment. Key growth drivers include increasing clinical trial complexity, adoption of decentralized trials, AI-driven analytics, and regulatory compliance demands.

U.S. hospitals are rapidly adopting AI and healthcare technology, with 71% now using predictive AI as of 2024, up from 66% in 2023. Leading healthcare tech companies like Tempus AI, OpenEvidence, Sword Health, and Huma are securing significant funding and valuations, while clinical documentation automation has reached 100% adoption in surveyed U.S. health systems. The global AI in healthcare market is projected to grow from $37.98 billion in 2025 to $928.18 billion by 2035 at a CAGR of 37.66%.

The global clinical data analytics market is valued at $132.89 billion in 2026 and is expected to reach $930.01 billion by 2034, growing at a 27.57% CAGR. North America leads the market, while Asia-Pacific shows rapid expansion. Cloud deployment dominates, with large enterprises leading adoption. Key drivers include AI/ML integration, EHR expansion, and value-based care initiatives. Pharmaceutical & life sciences segment leads end-user adoption, while public health and government sectors show significant growth potential.

ResearchAndMarkets.com released a comprehensive clinical trials review for Neurogenic Orthostatic Hypotension (nOH), analyzing global trial landscapes across regions, countries, phases, and sponsor types. The report identifies key trial locations, enrollment trends, and competitive dynamics to support strategic investment decisions in the nOH therapeutics market.

The disease registry software market is experiencing robust growth, expanding from $1.39 billion in 2024 to $1.55 billion in 2025 with an 11.2% CAGR through 2029. Growth drivers include rising chronic disease burden, increased clinical research, EHR adoption, and the shift toward value-based care and personalized medicine. Key developments include Health Catalyst's acquisition of Electronic Registry Systems and the launch of digital registries like the CONNECT-HCM Registry.

The Electronic Clinical Outcome Assessment (eCOA) Solutions Market is expected to grow from USD 1.57 billion in 2023 to USD 5.64 billion by 2032, with a 15.3% CAGR, driven by digital transformation in clinical research and increasing regulatory compliance requirements.

Certara announced Jon Resnick will become CEO on January 1, 2026, succeeding William Feehery. Resnick brings over 20 years of experience from IQVIA and previously worked in healthcare policy, bringing leadership expertise in health sciences and business operations.

Sabin Vaccine Institute has sent over 640 doses of its investigational cAd3-Marburg Vaccine to Ethiopia to combat the country's first Marburg virus disease outbreak, which has resulted in 13 confirmed infections and eight deaths.

The global generic drug Contract Research Organization (CRO) market is projected to grow from $8.74 billion in 2025 to $11.73 billion by 2034, with a 3.36% CAGR, driven by cost-efficient clinical development solutions and increasing generic drug approvals.

The global real world evidence (RWE) solutions market is projected to grow from $5.42 billion in 2025 to $10.83 billion by 2030, with a 14.8% CAGR, driven by value-based care, chronic disease prevalence, and advancements in healthcare data analytics.